Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
Sponsor: Alkermes, Inc.
Terminated
continuing study was no longer feasible
Other terminated trials from Alkermes, Inc.
- Schizophrenia · Phase PHASE4 · Mar 2025
- Schizoaffective Disorder, Depressive Type · Phase PHASE4 · Oct 2022
- Central Nervous System Diseases · Phase PHASE1 · Aug 2022
- Refractory Major Depressive Disorder · Phase PHASE3 · May 2020
- Healthy · Phase PHASE1 · Jan 2020
More terminations from Alkermes, Inc.
Other Heroin Dependence trials with similar outcome
This PHASE3 trial investigates Heroin Dependence and is currently terminated or withdrawn. Alkermes, Inc. leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Mar 2022 — Jan 2023 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Mar 2021 — Mar 2022 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
- New York State Psychiatric Institute
For direct contact, visit the study record on ClinicalTrials.gov .